Investor Relations

Latest Financial Results

Q3 2022

Quarter Ended June 30, 2022
Financial Results

Latest Annual Filing

For Fiscal Year Ending September 30, 2021

Company Overview

NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neuromuscular, neurological and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions.

IR Contacts

Headquarters

NeuBase Therapeutics, Inc.
350 Technology Drive
Pittsburgh, PA 15219
T: 412-763-3350
info@neubasetherapeutics.com

Investor Relations

LifeSci Advisors, LLC
Dan Ferry
1 International Place
14th Floor
Boston, MA 02110
T: 617-430-7576
daniel@lifesciadvisors.com

Transfer Agent

Standard Registrar and Transfer Company
440 East 400 South
Suite 200
Salt Lake City, UT 84111
T: 801-571-8844

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.